306 related articles for article (PubMed ID: 27074934)
1. Adverse Effects of Synthetic Cannabinoids: Management of Acute Toxicity and Withdrawal.
Cooper ZD
Curr Psychiatry Rep; 2016 May; 18(5):52. PubMed ID: 27074934
[TBL] [Abstract][Full Text] [Related]
2. "Spice" and "K2" herbal highs: a case series and systematic review of the clinical effects and biopsychosocial implications of synthetic cannabinoid use in humans.
Gunderson EW; Haughey HM; Ait-Daoud N; Joshi AS; Hart CL
Am J Addict; 2012; 21(4):320-6. PubMed ID: 22691010
[TBL] [Abstract][Full Text] [Related]
3. Critical Illness Secondary to Synthetic Cannabinoid Ingestion.
Kourouni I; Mourad B; Khouli H; Shapiro JM; Mathew JP
JAMA Netw Open; 2020 Jul; 3(7):e208516. PubMed ID: 32687586
[TBL] [Abstract][Full Text] [Related]
4. Assessing the experience of using synthetic cannabinoids by means of interpretative phenomenological analysis.
Kassai S; Pintér JN; Rácz J; Böröndi B; Tóth-Karikó T; Kerekes K; Gyarmathy VA
Harm Reduct J; 2017 Feb; 14(1):9. PubMed ID: 28187774
[TBL] [Abstract][Full Text] [Related]
5. Uses, Effects and Toxicity of Synthetic Cannabinoids from the Perspective of People with Lived Experiences.
Assi S; Marshall D; Bersani FS; Corazza O
J Psychoactive Drugs; 2020; 52(3):237-247. PubMed ID: 32027228
[TBL] [Abstract][Full Text] [Related]
6. A survey of synthetic cannabinoid consumption by current cannabis users.
Gunderson EW; Haughey HM; Ait-Daoud N; Joshi AS; Hart CL
Subst Abus; 2014; 35(2):184-9. PubMed ID: 24821356
[TBL] [Abstract][Full Text] [Related]
7. Intoxication by a synthetic cannabinoid (JWH-018) causes cognitive and psychomotor impairment in recreational cannabis users.
Theunissen EL; Reckweg JT; Hutten NRPW; Kuypers KPC; Toennes SW; Neukamm MA; Halter S; Ramaekers JG
Pharmacol Biochem Behav; 2021 Mar; 202():173118. PubMed ID: 33497715
[TBL] [Abstract][Full Text] [Related]
8. Toxicity of Synthetic Cannabinoids in K2/Spice: A Systematic Review.
de Oliveira MC; Vides MC; Lassi DLS; Torales J; Ventriglio A; Bombana HS; Leyton V; Périco CA; Negrão AB; Malbergier A; Castaldelli-Maia JM
Brain Sci; 2023 Jun; 13(7):. PubMed ID: 37508922
[TBL] [Abstract][Full Text] [Related]
9. Synthetic Cannabinoid-Associated Multiple Organ Failure: Case Series and Literature Review.
Armstrong F; McCurdy MT; Heavner MS
Pharmacotherapy; 2019 Apr; 39(4):508-513. PubMed ID: 30811628
[TBL] [Abstract][Full Text] [Related]
10. Distinct pharmacology and metabolism of K2 synthetic cannabinoids compared to Δ(9)-THC: mechanism underlying greater toxicity?
Fantegrossi WE; Moran JH; Radominska-Pandya A; Prather PL
Life Sci; 2014 Feb; 97(1):45-54. PubMed ID: 24084047
[TBL] [Abstract][Full Text] [Related]
11. Synthetic cannabinoid withdrawal: a new demand on detoxification services.
Macfarlane V; Christie G
Drug Alcohol Rev; 2015 Mar; 34(2):147-53. PubMed ID: 25588420
[TBL] [Abstract][Full Text] [Related]
12. K2--not the spice of life; synthetic cannabinoids and ST elevation myocardial infarction: a case report.
McKeever RG; Vearrier D; Jacobs D; LaSala G; Okaneku J; Greenberg MI
J Med Toxicol; 2015 Mar; 11(1):129-31. PubMed ID: 25154434
[TBL] [Abstract][Full Text] [Related]
13. Synthetic cannabinoid use disorder: an update for general psychiatrists.
Grigg J; Manning V; Arunogiri S; Lubman DI
Australas Psychiatry; 2019 Jun; 27(3):279-283. PubMed ID: 30663326
[TBL] [Abstract][Full Text] [Related]
14. International trends in spice use: Prevalence, motivation for use, relationship to other substances, and perception of use and safety for synthetic cannabinoids.
Loeffler G; Delaney E; Hann M
Brain Res Bull; 2016 Sep; 126(Pt 1):8-28. PubMed ID: 27108542
[TBL] [Abstract][Full Text] [Related]
15. A systematic review of adverse events arising from the use of synthetic cannabinoids and their associated treatment.
Tait RJ; Caldicott D; Mountain D; Hill SL; Lenton S
Clin Toxicol (Phila); 2016; 54(1):1-13. PubMed ID: 26567470
[TBL] [Abstract][Full Text] [Related]
16. Cannabis withdrawal in the United States: results from NESARC.
Hasin DS; Keyes KM; Alderson D; Wang S; Aharonovich E; Grant BF
J Clin Psychiatry; 2008 Sep; 69(9):1354-63. PubMed ID: 19012815
[TBL] [Abstract][Full Text] [Related]
17. A preliminary evaluation of synthetic cannabinoid use among adolescent cannabis users: Characteristics and treatment outcomes.
Blevins CE; Banes KE; Stephens RS; Walker DD; Roffman RA
Addict Behav; 2016 Dec; 63():114-9. PubMed ID: 27454353
[TBL] [Abstract][Full Text] [Related]
18. Psychosis and synthetic cannabinoids.
Deng H; Verrico CD; Kosten TR; Nielsen DA
Psychiatry Res; 2018 Oct; 268():400-412. PubMed ID: 30125871
[TBL] [Abstract][Full Text] [Related]
19. A Systematic Review of the Efficacy of Cannabinoid Agonist Replacement Therapy for Cannabis Withdrawal Symptoms.
Werneck MA; Kortas GT; de Andrade AG; Castaldelli-Maia JM
CNS Drugs; 2018 Dec; 32(12):1113-1129. PubMed ID: 30361897
[TBL] [Abstract][Full Text] [Related]
20. Impact of synthetic cannabinoids on the duration of opioid-related withdrawal and craving among patients of addiction clinics in Kazakhstan: A prospective case-control study.
Prilutskaya M; Bersani FS; Corazza O; Molchanov S
Hum Psychopharmacol; 2017 May; 32(3):. PubMed ID: 28631421
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
